Functional radioligation assays in dopaminergic receptors to evaluate the peptide neuroVAL as a treatment in an animal model of ASD induced by valproic acid

- 320885
Abstract
Favorite this paper
How to cite this paper?
Abstract

Binding assays are essential in drug screening, evaluating compound interactions with molecular targets, and are widely used in drug design and neurotransmitter-receptor studies. Neurotransmitters play a fundamental role in regulating motor activity, memory, behavior and brain development, with alterations in these systems often associated with dysfunctions observed in conditions such as Autism Spectrum Disorder (ASD), such as, for example, alterations in the dopaminergic system. Dopamine, the key neurotransmitter in this system, plays a crucial role in social behaviors, cognition, and the reward mechanism. Studies indicate that individuals with ASD show reduced dopaminergic responses in some brain areas and decreased dopamine release in others. These imbalances are associated with deficits in social interaction and the development of stereotyped behaviors, common in ASD. Given the limited therapeutic options for ASD, exploring bioinspired peptides like neuroVAL is crucial. This study aimed to standardize dopamine receptor binding assays to evaluate neuroVAL’s interaction with brain tissue from valproic acid (VPA)-induced ASD mice. Synaptosomes and neural membranes were extracted from female Swiss mice, following protocols approved by the Animal Ethics Committee (CEUA) of the University of Brasília. Extraction protocols, incubation time, temperature, and buffer conditions were standardized for reproducibility. Competition, saturation, and uptake assays were performed using tritiated dopamine (³H-dopamine) and neuroVAL. Results showed a significant increase in radioactive binding to dopamine receptors with the peptide, suggesting interaction and modulation. In uptake assays, the expected decrease in ³H-dopamine uptake occurred with increasing non-radioactive dopamine. Interestingly, neuroVAL slightly increased dopamine uptake, indicating potential modulatory effects. Statistical analysis suggested further investigation. This study suggests that neuroVAL may modulate dopaminergic receptors, crucial given the dopaminergic dysfunction in ASD. Standardizing binding assays is vital to accurately quantify receptor interactions in brain tissue from VPA-induced ASD mice. Despite promising results, further protocol optimization is needed for reliability. Future studies should refine assays and validate neuroVAL’s therapeutic potential for ASD treatment.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Universidade de Brasília | (University of Brasília)
  • 2 University of Brasília
Track
  • Peptides and neurological disorders
Keywords
Binding assays
Dopaminergic system
Autism Spectrum Disorder (ASD)
Peptide
NeuroVAL